Yokota, Tomoya
Zenda, Sadamoto
Kodaira, Takeshi
Kiyota, Naomi
Fujimoto, Yasushi
Wasano, Koichiro
Takahashi, Ryo
Mizowaki, Takashi
Homma, Akihiro
Sasaki, Keita
Machida, Ryunosuke
Sekino, Yuta
Fukuda, Haruhiko
,
,
Funding for this research was provided by:
Japan Agency for Medical Research and Development (22ck0106751h0001, 22ck0106751h0001, 22ck0106751h0001, 22ck0106751h0001, 22ck0106751h0001, 22ck0106751h0001, 22ck0106751h0001, 22ck0106751h0001, 22ck0106751h0001)
National Cancer Center Research and Development Funds (2023-J-3, 2023-J-3, 2023-J-3, 2023-J-3, 2023-J-3, 2023-J-3, 2023-J-3, 2023-J-3, 2023-J-3, 2023-J-3, 2023-J-3, 2023-J-3, 2023-J-3, 2023-J-3, 2023-J-3)
Article History
Received: 20 September 2023
Accepted: 9 October 2023
First Online: 6 November 2023
Declarations
:
: The study protocol was approved by the National Cancer Center Hospital East Certified Review Committee (CRB) on January 2021 first (CRB3180009). Modifications to the study protocol will be communicated to the CRB. The CRB will revise the informed consent materials to be given to participants and adapt them in accordance with the institution’s guidelines. The study protocol was revised as version 1.4.0 as of March 2023. Participants’ personal information such as names and addresses will not be collected.All patients will be required to provide written informed consent to participate.This trial is performed in accordance with the Clinical Trials Act, the Enforcement Rules for the Clinical Trials Act and relevant notifications published by Japan’s Ministry of Health, Labour, and Welfare and the modified Act on the Protection of Personal Information as well as the Declaration of Helsinki.
: All patients will be required to provide written informed consent for the publication of the results.
: The authors declare no competing interests.